Salarius Pharmaceuticals Inc (SLRX) - Total Liabilities
Based on the latest financial reports, Salarius Pharmaceuticals Inc (SLRX) has total liabilities worth $1.85 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Salarius Pharmaceuticals Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Salarius Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Salarius Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.
Salarius Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Salarius Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Duksung Co Ltd
KO:004835
|
Korea | ₩54.37 Billion |
|
Lenox Pasifik Investama Tbk PT
JK:LPPS
|
Indonesia | Rp139.57 Million |
|
Proactis SA
PA:PROAC
|
France | €9.67 Million |
|
Huachen AI Parking Management Technology Holding Co Ltd
NASDAQ:HCAI
|
USA | $21.65 Million |
|
Pacific Strategic Financial
JK:APIC
|
Indonesia | Rp4.41 Trillion |
|
Anglo Asian Mining Plc
LSE:AAZ
|
UK | GBX84.38 Million |
|
DomaCom Limited
AU:DCL
|
Australia | AU$6.24 Million |
|
Chenghe Acquisition II Co.
NYSE MKT:CHEB
|
USA | $6.90 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Salarius Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Salarius Pharmaceuticals Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Salarius Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Salarius Pharmaceuticals Inc (2014–2024)
The table below shows the annual total liabilities of Salarius Pharmaceuticals Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.51 Million | +16.32% |
| 2023-12-31 | $1.30 Million | -69.55% |
| 2022-12-31 | $4.27 Million | +102.10% |
| 2021-12-31 | $2.11 Million | -23.88% |
| 2020-12-31 | $2.77 Million | -16.31% |
| 2019-12-31 | $3.31 Million | +199.33% |
| 2018-12-31 | $1.11 Million | -81.20% |
| 2017-12-31 | $5.89 Million | +51.04% |
| 2016-12-31 | $3.90 Million | +35.45% |
| 2015-12-31 | $2.88 Million | -93.17% |
| 2014-12-31 | $42.15 Million | -- |
About Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufac… Read more